Department of neurology, hôpital Lariboisière, 2, rue Ambroise-Paré, 75475 Paris cedex 10, France; Inserm unit U740, université Paris Diderot Paris 7, UFR de médecine Paris Diderot Paris 7 (site Villemin), 10, avenue de Verdun, 75010 Paris, France; Paris 7 university, DHU neurovasc Sorbonne Paris-Cité, 190, avenue de France, 75013 Paris, France; Department of neurology, Framingham heart study, Boston university school of medicine, 72 E Concord St, Boston, MA 02118, USA.
Rev Neurol (Paris). 2013 Oct;169(10):757-64. doi: 10.1016/j.neurol.2013.07.022. Epub 2013 Sep 12.
Delaying the onset of dementia by just a few years could have a major impact on the prevalence of the disease at the population level. Vascular risk factors are modifiable and may offer an important opportunity for preventive approaches. Several studies have shown that diabetes, hypertension, obesity, and smoking are associated with an increased risk of cognitive decline and dementia, but other groups have not observed such a relation. Positive associations were observed mainly in studies where risk factors were assessed in midlife, suggesting that age is an important modulator in the relation between vascular risk factors and cognition. The population attributable risk of dementia is particularly high for hypertension. Associations of vascular risk factors with cognitive decline and dementia are probably mediated largely by cerebrovascular disease, including both stroke and covert vascular brain injury, which can have additive or synergistic effects with coexisting neurodegenerative lesions. To date, randomized trials have not convincingly demonstrated that treating vascular risk factors is associated with a reduction in cognitive decline or dementia risk. Of eight randomized trials testing the effect of antihypertensive agents on dementia risk, only one was positive, and another in a subgroup of individuals with recurrent stroke. In most trials, cognition and dementia were secondary outcomes, follow-up was short and treatment was initiated at an older age. No effect on cognitive decline or dementia could be demonstrated for statins and intensive glycemic control. Future areas of investigation could include differential class effects of antihypertensive drugs on cognitive outcomes and identification of high risk individuals as target population for clinical trials initiated in midlife.
将痴呆症的发病时间推迟几年,可能会对人群层面上该疾病的患病率产生重大影响。血管危险因素是可以改变的,这可能为预防方法提供了一个重要机会。一些研究表明,糖尿病、高血压、肥胖症和吸烟与认知能力下降和痴呆症的风险增加有关,但其他研究并未观察到这种关联。阳性关联主要出现在在中年期评估风险因素的研究中,这表明年龄是血管危险因素与认知之间关系的一个重要调节剂。高血压导致痴呆症的人群归因风险特别高。血管危险因素与认知能力下降和痴呆症的关联可能主要通过脑血管疾病来介导,包括中风和隐匿性血管性脑损伤,这些疾病与并存的神经退行性病变具有相加或协同作用。迄今为止,随机试验尚未令人信服地证明治疗血管危险因素与降低认知能力下降或痴呆症风险有关。在八项测试抗高血压药物对痴呆症风险影响的随机试验中,只有一项是阳性的,另一项是在复发性中风的亚组中。在大多数试验中,认知和痴呆症是次要结局,随访时间短,治疗开始于老年。他汀类药物和强化血糖控制对认知下降或痴呆症均无影响。未来的研究领域可能包括抗高血压药物对认知结果的不同类别影响,以及确定作为从中年开始进行临床试验的目标人群的高危个体。